The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting the significant hurdles biotech firms face in developing advanced oncology treatments, Exelixis shares faced heavy selling pressure. The STELLAR-303 study of zanzalintinib failed to reach statistical significance in overall survival for a key colorectal cancer subgroup. According to reports, this failure raises uncertainty regarding the regulatory approval prospects and commercial viability of the drug for this specific indication.
This setback comes at a critical time for the biotech sector, as investors closely monitor clinical trial results from peers such as Merck, which previously reported strong data for Keytruda in similar indications. Compared to historical performance, Phase 3 failures often trigger portfolio rebalancing, especially since zanzalintinib was viewed as a future growth driver to offset potential slowing sales of the company's flagship drug, Cabometyx.
Sign in to access this content
Sign InLooking at price action, EXEL shares are under watch following the close on June 23, 2026, as markets digest the clinical data. Regarding upcoming catalysts, traders are looking toward the U.S. Retail Sales data scheduled for June 17, 2026, which may influence broader market sentiment and risk appetite for mid-cap healthcare stocks.